This Cancer Research Program will be carried out in cooperation with the other member institutions of the Southwest Oncology Group. It involves the Combined Modality (Medical Oncology, Hematology, Surgical Oncology, Radiation Oncology, and Pathology) Approach to the management of adult patients with malignant disease. The principal investigator and the other participants in this effort have had broad experience in cooperative therapeutic research. We have successfully collaborated in a Combined Modality Program in the Southwest Oncology Group. The Investigators listed have made major contributions to the Group effort in administrative capacity: Chairman of the Southwest Oncology Group (Charles A. Coltman, Jr., M.D.), Principal Investigator of the Southwest Oncology Group Operations Office grant at the Cancer Therapy and Research Center (Charles A. Coltman, Jr., M.D.); Associate Chairman, Breast Cancer Committee (William L. McGuire, M.D.); Executive Officer, Southwest Oncology Group (Daniel L. Kisner, M.D.), Chairman, Quality Assurance Committee (Daniel L. Kisner, M.D.); Chairman, Breast Cancer Committee (C. Kent Osborne, M.D.); Chairman, New Agents and Pharmacology Committee (Daniel D. Von Hoff, M.D.); Assistant Chairman, Breast Cancer Committee (William A. Knight, III, M.D.); Group Leader, Distributive Data Management System (Gary M. Clark, Ph.D.); Chairman, Leukemia Committee (John J. Hutton, M.D.); Chairman, Surgical Quality Control Committee (Anatolio B. Cruz, M.D.). In addition, they have made major scientific and patient accrual contributions. A total of 469 patients have been registered from January 1980 to December 1982, 139 of which have been registered in 1982.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA022433-08
Application #
3556650
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1987-12-31
Budget Start
1985-01-01
Budget End
1985-12-31
Support Year
8
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8

Showing the most recent 10 out of 257 publications